Kindred Biosciences Inc (NASDAQ:KIN) has earned a consensus rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $9.88.

KIN has been the subject of a number of research analyst reports. B. Riley set a $11.00 price objective on Kindred Biosciences and gave the stock a “buy” rating in a report on Tuesday, December 5th. Zacks Investment Research upgraded Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Wednesday, September 27th. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Finally, HC Wainwright set a $10.00 price objective on Kindred Biosciences and gave the stock a “buy” rating in a report on Tuesday, December 5th.

Several hedge funds have recently modified their holdings of the stock. Virtu KCG Holdings LLC boosted its stake in shares of Kindred Biosciences by 41.7% in the second quarter. Virtu KCG Holdings LLC now owns 15,285 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 4,495 shares during the period. Goldman Sachs Group Inc. raised its position in Kindred Biosciences by 28.5% during the first quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 4,954 shares in the last quarter. Wells Fargo & Company MN raised its position in Kindred Biosciences by 2.2% during the third quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock valued at $2,650,000 after purchasing an additional 7,206 shares in the last quarter. Prudential Financial Inc. raised its position in Kindred Biosciences by 18.9% during the third quarter. Prudential Financial Inc. now owns 52,920 shares of the biopharmaceutical company’s stock valued at $415,000 after purchasing an additional 8,410 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Kindred Biosciences by 17.5% during the third quarter. Bank of New York Mellon Corp now owns 74,548 shares of the biopharmaceutical company’s stock valued at $586,000 after purchasing an additional 11,081 shares in the last quarter. Institutional investors and hedge funds own 66.85% of the company’s stock.

Kindred Biosciences (NASDAQ:KIN) remained flat at $$7.70 during trading on Monday. The stock had a trading volume of 51,542 shares, compared to its average volume of 142,266. Kindred Biosciences has a 1-year low of $4.15 and a 1-year high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. equities analysts expect that Kindred Biosciences will post -1.19 earnings per share for the current fiscal year.

WARNING: “Kindred Biosciences Inc (KIN) Given Consensus Rating of “Buy” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/kindred-biosciences-inc-kin-given-consensus-rating-of-buy-by-analysts-2.html.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.